Thank you for being here today, Madam Secretary. Thank you. I wanted to start off with your goal of shutting down the education department.You've previously said that Congress could pass legislation to do that next year. Do you still expect that to be the timeline. Uh I don't know that I have said that they could do it next year.Uh I I don't know what the timeline is going to be, but clearly the Department of Education cannot close without congressional action and consent. So it is my goal to continue to wo ...

Getting Funded In Black Media: Who Owns The Story—and The Capital? https://t.co/l8yjaVB9jh https://t.co/gXZAScATAc ...

DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange ...

Core Viewpoint - FOXO Technologies Inc. has executed an agreement to issue 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock for net proceeds of $1,500,000, indicating a strategic move to enhance its financial position and support growth initiatives [1][2]. Financial Summary - The issuance of Series A Preferred Stock is expected to generate gross proceeds of $1,650,000, with the company agreeing to pay investor costs of $150,000 [2]. - The first closing of this transaction occurred on June 4, 2025, with subsequent closings planned based on the effective date of a registration statement [2]. - In the first quarter of 2025, FOXO reported over $3 million in net revenues and a $4.4 million improvement in stockholders' equity, bringing total stockholders' equity to $9.7 million as of March 31, 2025, compared to a negative $17.5 million as of September 30, 2024 [3]. Company Overview - FOXO Technologies operates three subsidiaries: Rennova Community Health, which runs a critical access hospital in East Tennessee; Myrtle Recovery Centers, a behavioral health facility; and FOXO Labs, a biotechnology company focused on health and lifespan improvement through innovative technology [4][5].

Summary of Royalty Pharma Conference Call Company Overview - Royalty Pharma is one of the largest funders of life sciences globally and the largest in royalty-based funding, with over 25 years of experience [4][6] - The company went public in 2020 and currently generates over $3 billion in revenue [6][8] - Royalty Pharma owns royalties on approximately 40-45 products, with a business model focused on capital deployment and shareholder returns [7][8] Key Portfolio Assets - Recent investment includes a $250 million R&D funding deal with Biogen for a lupus drug, litafilimab, which is in phase three trials [18][19] - The lupus market is seen as under-penetrated, with significant growth potential anticipated [20][22] - Other notable investments include royalties from MorphoSys and products in the inflammatory bowel disease (IBD) space [26][28] Investment Strategy - The company emphasizes investing in products that are meaningful to patients rather than solely focusing on attractive returns [11][12] - A rigorous vetting process is employed to assess potential investments, involving a deep diligence process [10][11] - Royalty Pharma has developed a synthetic royalty model to provide funding against specific drugs or R&D programs, filling a gap in the funding landscape [15][16] Market Dynamics - The company views its business as having a countercyclical nature to the biopharma funding environment, with a consistent need for capital in the industry [14][15] - The funding environment is currently challenging, but Royalty Pharma has successfully deployed capital into promising products [16] Recent Developments - The company has internalized its management structure, aligning the interests of the team with shareholders [42][46] - A $3 billion buyback program was announced, reflecting a commitment to shareholder value [46][47] - Guidance for portfolio receipts was raised due to favorable foreign exchange rates and growth in existing royalties [48][49] Diligence and Data Analytics - Royalty Pharma has invested significantly in its diligence platform, employing a generalist approach to evaluate various therapeutic areas [54][55] - The company utilizes extensive data sources and real-world evidence to conduct deep market evaluations [55][57] Conclusion - Royalty Pharma is positioned as a key player in the biopharma funding landscape, with a strong focus on meaningful product investments and a robust diligence process. The company is optimistic about future growth opportunities in various therapeutic areas, particularly lupus and cardiovascular diseases [20][34][46]

Acadia Healthcare Company (ACHC) 2025 Conference Summary Industry Overview - Acadia Healthcare is one of the largest behavioral health providers in the US, operating a network of 270 facilities with approximately 12,000 beds across 39 states and Puerto Rico, serving over 80,000 patients daily [6][7][8]. Key Financial Performance - The company reported that revenue, EBITDA, volume, revenue per day, and margins were all in line with guidance, with EBITDA at the high end of the range [2][3]. - Acadia added 378 newly licensed beds in Q1 and reaffirmed its full-year financial guidance for both revenue and adjusted EBITDA [3][4]. Demand and Growth Outlook - Consistent demand is observed across all four lines of business, with a significant opportunity in the behavioral health sector due to an estimated 75,000 additional beds needed in the US to meet demand [6][7]. - The company is in a period of record growth, expecting to add 800 to 1,000 beds in 2025, with nearly half already achieved in Q1 [10][11]. - The Comprehensive Treatment Centers (CTCs) segment is expected to grow mid-single digits over the next few years, with a strong demand for opioid use disorder treatment [9][15]. Operational Insights - The average cost per new facility bed is estimated at $500,000 to $550,000, with a target breakeven period of 12 to 13 months and expected maturity occupancy of 80% to 85% within three to five years [12][13]. - The company is focused on tuck-in M&A to acquire existing CTCs, which is a fragmented part of healthcare, enhancing growth and efficiency [18]. Policy and Regulatory Environment - Acadia is monitoring the implications of the opioid settlement funds, with $50 billion available but only a small percentage reaching states and counties [19][20]. - The company is optimistic about the potential impact of the reconciliation bill on access to high acuity mental health care, which could mitigate costs in other healthcare areas [24][25]. Pricing and Revenue Guidance - The company anticipates low single-digit pricing growth, with supplemental payments being a significant factor in revenue projections [46][47]. - For 2025, Acadia expects revenue growth of 6%, but EBITDA is projected to decline year-over-year due to various headwinds, including supplemental payment reductions and underperforming facilities [52][53]. Challenges and Risks - The company faces challenges from underperforming facilities, which are expected to impact EBITDA by approximately $20 million for the year [34][38]. - There is ongoing concern regarding potential policy changes and their impact on Medicaid access and reimbursement rates [26][30]. Conclusion - Acadia Healthcare is positioned for growth in the behavioral health sector, with strong demand and strategic plans for bed additions and acquisitions. However, it must navigate regulatory challenges and operational headwinds to achieve its financial targets [41][44].

LAS VEGAS, May 09, 2025 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), Transforming the Landscape of Social Commerce, Social Telehealth and Social Crowdfunding with MARKET.live; VANITYPrescribed; GoodGirlRx; and the GO FUND YOURSELF TV Show, today announced that VERB CEO Rory J. Cutaia will host a conference call to discuss the Company’s financial results for the first quarter 2025 on Tuesday, May 13, 2025, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). Fin ...

Bio-Techne (TECH) Q3 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Good morning, and welcome to Bio Techne Earnings Conference Call for the Third Quarter of Fiscal Year twenty twenty five. At this time, all participants have been placed in listen only mode, and the call will be opened for questions following the management's prepared remarks. During our Q and A session, please limit yourself to one question and a follow-up. I would now like to turn the call over to David Claire, Bio Vice President, I ...

LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), Transforming the Landscape of Social Commerce, Social Telehealth and Social Crowdfunding with MARKET.live, VANITYPrescribed, GoodGirlRx, and the GO FUND YOURSELF TV Show, today announced that CEO Rory J. Cutaia was featured on Cheddar TV's Power Players live from the floor of the NY Stock Exchange on an episode that airs Friday, May 9, 2025, at 8PM ET. Hosted by J.D. Durkin, Power Players dive ...

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were approximately $585 million, representing a 4.2% decline compared to $611 million in Q1 2024. On a currency neutral basis, this reflects a 1.5% year-over-year decrease, primarily driven by lower sales in the Life Science Group [11][12] - GAAP gross margin for Q1 2025 was 52.3%, down from 53.4% in Q1 2024, attributed to increased restructuring costs [13] - Non-GAAP gross margin for Q1 2025 was 53.8%, lower than 54.2% in Q1 2024, while non-GAAP operating margin improved to 10.8% from 9.7% year-over-year [15][16] - GAAP net income for Q1 2025 was $71 million, or $2.54 diluted earnings per share [17] Business Line Data and Key Metrics Changes - Life Science Group sales in Q1 2025 were $229 million, down 5.4% on a reported basis and 3.5% on a currency neutral basis, reflecting ongoing softness in the biotech and academic research market [12] - Clinical Diagnostics Group sales were approximately $357 million, a decrease of 3.2% on a reported basis, but effectively flat on a currency neutral basis [13] - Process Chromatography business experienced mid-teens growth year-over-year, with expectations of high single-digit growth for 2025 [12][19] Market Data and Key Metrics Changes - In the Americas and Asia Pacific, currency neutral sales decreased, partially offset by increased sales in EMEA [12] - Demand for consumables remained strong, while instrument sales faced challenges, particularly in the academic and biotech sectors [41][71] Company Strategy and Development Direction - The company is focused on driving consistent top-line growth and operational efficiency to achieve substantial margin expansion over the coming years [27] - The acquisition of Stila Technology is on track for closing by the end of Q3 2025, which will enhance the company's digital PCR offerings [8][10] - The company is implementing mitigation strategies for tariff impacts, including surcharges and regionalizing supply chains [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macro environment with academic market headwinds due to government funding and global trade disruptions [5] - The company expects total currency neutral revenue to decline by approximately 1% to 1.5% for 2025, reflecting softer academic research funding and reduced demand from biotech customers [20][21] - Management remains optimistic about the long-term growth potential in life sciences and diagnostics despite current challenges [28][29] Other Important Information - The company generated $130 million in net cash from operating activities in Q1 2025, compared to $70 million in Q1 2024 [18] - Free cash flow for Q1 2025 was $96 million, significantly higher than $30 million in Q1 2024, with a full-year target of approximately $310 million to $330 million for 2025 [18][19] Q&A Session Summary Question: Impact of tariffs on guidance - Management discussed the gross impact of tariffs and mitigation efforts, including potential surcharges and pre-positioning inventory [33][36] Question: Academic funding expectations - Management noted a 28% reduction in overall funding and challenges in instrument sales, while consumables remained strong [39][40] Question: Growth gap between consumables and equipment - Instrument sales saw a sequential decline of about 10%, while consumables held up well [46] Question: Tariff exposure specifics - Management clarified that the majority of revenue in China comes from U.S. products, with ongoing evaluations of tariff impacts [47][49] Question: Free cash flow maintenance despite lower operating margin - Management emphasized focus on working capital management and inventory control to sustain free cash flow [96]